Vascular Endothelial Growth Factor Inhibitors Market Segmentation:
Route of Administration Segment Analysis
The injectable subsegment in the route of administration segment in the vascular endothelial growth factor (VEGF) inhibitors market is expected to hold the highest market share of 71% within the forecast period due to its superior bioavailability and rapid therapeutic effect. Most VEGF inhibitors, particularly monoclonal antibodies, require injection for effective delivery. As per a report by NLM January 2023, in Japan, rates of anti-VEGF injections, sex- and age-adjusted per 1000 person-years, increased from 7.9 to 16.1 in the last ten years. This shows the significant rise in medical injections in the treatment of vision-threatening and cancer-related disorders.
Type Segment Analysis
The VEGF‑A inhibitors subsegment in the market is expected to hold the highest market share in the type segment within the forecast period due to its central role in pathological angiogenesis and its proven effectiveness across multiple major indications such as cancer and age-related macular degeneration. VEGF‑A drives both tumor vascularization and retinal neovascularization and vascular permeability, so inhibitors targeting VEGF‑A (e.g., bevacizumab, ranibizumab, aflibercept) form the backbone of therapeutic regimens. Their widespread clinical use is further supported by established guidelines and approvals from major health authorities such as the FDA and EMA.
End user Segment Analysis
The hospital subsegment in the vascular endothelial growth factor (VEGF) inhibitors market is expected to hold the highest market share in the end user segment within the forecast period due to hospitals’ superior infrastructure, access to specialist physicians, and ability to manage severe cases that require advanced care. As per a report by NLM in September 2023, in the last decade, 901,826 injections of VEGF inhibitors were administered to 56,081 patients in hospitals in Denmark; 131,010 injections were given in 2022 alone. Such a large number of injections were given in the hospital, underlining the crucial role these hospitals play in administering VEGF inhibitor therapies to patients who require special medical attention.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Sub-segments |
|
Type |
|
|
Drug Class |
|
|
Application |
|
|
Route of Administration |
|
|
End user |
|
|
Distribution Channel |
|
